Engineered immune cells take on tough blood cancers
NCT ID NCT07162571
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage trial tests a personalized cell therapy called CD19/22 CAR-T cells in 17 adults with relapsed or refractory acute lymphoblastic leukemia or B-cell lymphoma. Patients receive their own immune cells that have been reprogrammed to target and kill cancer cells. The study aims to check safety and whether the treatment can shrink or eliminate the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD19/22 CAR-T cells (a type of immune cell therapy)
What this could lead to
If successful, this could offer a new treatment option for adults with hard-to-treat leukemia or lymphoma that has come back or not responded to standard therapy.
What could go wrong
This is an early-phase trial with only 17 participants, so results may not apply broadly. CAR-T therapy can cause severe side effects like cytokine release syndrome or neurological issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
State Institution Minsk Scientific and Practical Center for Surgery, Transplantology, and Dermatology
Minsk, 220087, Belarus
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact